Dear Ms. Gambino:

Please refer to your Supplemental New Drug Applications (sNDA) dated and received, June 8, 2017 (NDAs 019839/S-091 and 020990/S-049), and June 30, 2017 (NDAs 019839/S-093 and 020990/S-050), and your amendments, submitted under section 505(b) of the Federal Food, Drug, and Cosmetic Act (FDCA) for Zoloft (sertraline hydrochloride) tablets, 25 mg, 50 mg, and 100 mg (NDA 019839), and Zoloft (sertraline hydrochloride) oral solution, 20 mg/mL (NDA 020990).

These supplemental new drug applications provide for the following changes to product labeling:

sNDA 019839/S-091; sNDA 020990/S-049

These “Changes Being Effected” supplemental new drug applications propose to add "rhabdomyolysis" to the Post-marketing Experience subsection (6.2).

sNDA 019839/S-093; sNDA 020990/S-050

These Prior Approval supplemental new drug applications proposes to add the following labeling revisions based upon your Postmarketing Requirement study report: 1) revisions to the Highlights section, 2) a new subsection under Warnings and Precautions entitled QTc Prolongation (5.10), Clinically Significant Drug Interactions (7.1), and Pharmacodynamics (12.2).

APPROVAL & LABELING

We have completed our review of these supplemental applications, as amended. They are approved, effective on the date of this letter, for use as recommended in the enclosed, agreed-upon labeling text.
We note that your December 6, 2017 (for sNDA 019839/S-093; sNDA 020990/S-050), submission includes final printed labeling (FPL) for your package insert and Medication Guide. We have not reviewed this FPL. You are responsible for assuring that the wording in this printed labeling is identical to that of the approved content of labeling in the structured product labeling (SPL) format.

**WAIVER OF HIGHLIGHTS SECTION**

Please note that we have previously granted a waiver of the requirements of 21 CFR 201.57(d)(8) regarding the length of Highlights of prescribing information.

**CONTENT OF LABELING**

As soon as possible, but no later than 14 days from the date of this letter, submit the content of labeling [21 CFR 314.50(l)] in structured product labeling (SPL) format using the FDA automated drug registration and listing system (eLIST), as described at http://www.fda.gov/ForIndustry/DataStandards/StructuredProductLabeling/default.htm. Content of labeling must be identical to the enclosed labeling (text for the package insert, Medication Guide), with the addition of any labeling changes in pending “Changes Being Effected” (CBE) supplements, as well as annual reportable changes not included in the enclosed labeling.

Information on submitting SPL files using eList may be found in the guidance for industry titled “SPL Standard for Content of Labeling Technical Qs and As” at http://www.fda.gov/downloads/DrugsGuidanceComplianceRegulatoryInformation/Guidances/UCM072392.pdf.

The SPL will be accessible from publicly available labeling repositories.

Also within 14 days, amend all pending supplemental applications that include labeling changes for this NDA, including CBE supplements for which FDA has not yet issued an action letter, with the content of labeling [21 CFR 314.50(l)(1)(i)] in MS Word format, that includes the changes approved in this supplemental application, as well as annual reportable changes and annotate each change. To facilitate review of your submission, provide a highlighted or marked-up copy that shows all changes, as well as a clean Microsoft Word version. The marked-up copy should provide appropriate annotations, including supplement number(s) and annual report date(s).

**REQUIRED PEDIATRIC ASSESSMENTS**

Under the Pediatric Research Equity Act (PREA) (21 U.S.C. 355c), all applications for new active ingredients, new indications, new dosage forms, new dosing regimens, or new routes of administration are required to contain an assessment of the safety and effectiveness of the product for the claimed indication(s) in pediatric patients unless this requirement is waived, deferred, or inapplicable.

Reference ID: 4192847
Because none of these criteria apply to your application, you are exempt from this requirement.

**FULFILLMENT OF POSTMARKETING REQUIREMENT**

We have received your submission dated June 30, 2017, containing the final report for the following postmarketing requirement listed in the July 16, 2014, postapproval postmarketing requirement letter.

2174-1 A single-center randomized, placebo-controlled and active-controlled thorough QT (TQT) trial in normal (or healthy) subjects. Please refer to ICH E14 guidance to design the trial and submit the protocol to the agency for comments. The doses studied should ensure the clinical concentration-response relationship for QTc prolongation is characterized, including exploration of higher concentrations than those achieved following the anticipated therapeutic dose. Include the highest tolerable dose in the trial. Because N-desmethylsertraline, the primary metabolite of sertraline, has a much longer elimination half-life (62-104 hours) compared to the parent drug (26 hours), conduct the TQT study at steady state.

We have reviewed your submission and conclude that the above requirement was fulfilled.

This completes all of your postmarketing requirements and postmarketing commitments acknowledged in our July 16, 2014, letter.

**REPORTING REQUIREMENTS**

We remind you that you must comply with reporting requirements for an approved NDA (21 CFR 314.80 and 314.81).

If you have any questions, please email Simran Parihar, PharmD, at simran.parihar@fda.hhs.gov.

Sincerely,

{See appended electronic signature page}

Mitchell V. Mathis, M.D.
Director
Division of Psychiatry Products
Office of Drug Evaluation I
Center for Drug Evaluation and Research

ENCLOSURE:
Content of Labeling
This is a representation of an electronic record that was signed electronically and this page is the manifestation of the electronic signature.

/s/

MITCHELL V Mathis
12/08/2017